Hypertension – Pipeline Review, H2 2019

Publication Month: Feb 2020 | No. of Pages: 120 Published By: Global Markets Direct
Single User License: US $ 2000
Corporate User License: US $ 6000

“Global Markets Direct’s, ‘Hypertension – Pipeline Review, H2 2019’, provides an overview of the Hypertension pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Hypertension, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hypertension and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real-time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios enhance decision-making capabilities and help to create effective counter-strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.”


– The report provides a snapshot of the global therapeutic landscape of Hypertension

– The report reviews pipeline therapeutics for Hypertension by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Hypertension therapeutics and enlists all their major and minor projects

– The report assesses Hypertension therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews the latest news related to pipeline therapeutics for Hypertension”

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with the potentially strong product portfolio and create effective counter-strategies to gain a competitive advantage

Identify and understand important and diverse types of therapeutics under development for Hypertension

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Hypertension pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

“A1M Pharma AB

Aadi Bioscience Inc

Abivax SA

Acceleron Pharma Inc

Actelion Pharmaceuticals Ltd

Adhera Therapeutics

Aerogen Ltd

Aggamin LLC

AI Therapeutics

Ajanta Pharma Ltd

Alnylam Pharmaceuticals Inc

Altavant Sciences Inc

AMAG Pharmaceuticals Inc

AnGes Inc



Apollo Therapeutics LLC

APT Therapeutics Inc

Aqualung Therapeutics Corp

Attgeno AB

ATXA Therapeutics Ltd

AVEO Oncology Inc

Bayer AG

Beijing Wehand-Bio Pharmaceutical Co Ltd

Bial – Portela & Ca SA

Biogen Inc

BioRestorative Therapies Inc

BioStem Technologies Inc

Boehringer Ingelheim International GmbH

Boryung Pharmaceutical Co Ltd

Bristol-Myers Squibb Co

C4X Discovery Holdings Plc

Camurus AB

Capricor Therapeutics Inc

CardioPharma Inc

Cellmid Ltd

Celsion Corp

Celtaxsys Inc

Chiesi Farmaceutici SpA

Chong Kun Dang Pharmaceutical Corp

Chugai Pharmaceutical Co Ltd

CinCor Pharma Inc

CJ HealthCare Corp

Complexa Inc

CSPC Pharmaceutical Group Ltd

Cumberland Pharmaceuticals Inc

D. Western Therapeutics Institute Inc

Daewon Pharmaceutical Co Ltd

Daewoong Co Ltd

Daewoong Pharmaceutical Co Ltd

Daiichi Sankyo Co Ltd

Denovo Biopharma LLC

Eldrug SA

Eli Lilly and Co

Elyson Pharmaceutical Co Ltd

Esperion Therapeutics Inc

Excubio Pharmaceuticals Inc

FunPep Co Ltd

Galectin Therapeutics Inc

Gemphire Therapeutics Inc

GenKyoTex SA

GenThera Inc

GEXVal Inc

Gilead Sciences Inc

Gmax Biopharm Ltd

Gossamer Bio Inc

Guangzhou Magpie Pharmaceutical Co Ltd

H. Lundbeck AS

Hanmi Pharmaceuticals Co Ltd

Hetero Labs Ltd

Himuka AM Pharma Corp

Idorsia Pharmaceutical Ltd

Innolife Co Ltd

Innopharmax Inc

Insmed Inc

Insys Therapeutics Inc

Inven2 AS

INVENT Pharmaceuticals Inc

Ionis Pharmaceuticals Inc

Japan Tobacco Inc

Jeil Pharmaceutical Co Ltd

Jiangsu Hengrui Medicine Co Ltd

KBP BioSciences Co Ltd

Kyowa Kirin Co Ltd

Kyung Dong Co Ltd

Larix Bioscience LLC

Lee’s Pharmaceutical Holdings Ltd

Les Laboratoires Servier SAS

LG Chem Ltd

Liaoning Haiwang Biotechnoloty Co Ltd

LinXis BV

Liquidia Technologies Inc

LTT Bio-Pharma Co Ltd

Martin Pharmaceuticals Inc

Merck & Co Inc

Mezzion Pharma Co Ltd


Morphogen-IX Ltd

Nippon Shinyaku Co Ltd

Nissan Chemical Corp

Noorik Biopharmaceuticals AG

Northern Therapeutics Inc

Novartis AG

NuSirt Biopharma Inc

Omeros Corp

Orion Corp

Overseas Pharmaceuticals Ltd

Panorama Research Inc

Park Active Molecules

Pharming Group NV

Pharmosa Biopharm Inc

PhaseBio Pharmaceuticals Inc

Proteo Inc

Pulmokine Inc

Q BioMed Inc

QR Pharmaceuticals Ltd

Quantum Genomics SA

Radikal Therapeutics Inc

Reata Pharmaceuticals Inc

Relief Therapeutics Holding AG

Relypsa Inc

Renova Therapeutics Inc

Respira Therapeutics Inc

Resverlogix Corp

Reviva Pharmaceuticals Inc

Ridge Therapeutics LLC

RMJ Holdings LLC

Samik Pharmaceutical Co Ltd


Sarfez Pharmaceuticals Inc

Schrodinger LLC

Scipharm SaRL

Scohia Pharma Inc

Shanghai Pharmaceutical Co Ltd

Shanghai Xinyi Pharmaceutical Co Ltd

Shenzhen Salubris Pharmaceuticals Co Ltd

SJT Molecular Research SL

Sorrento Therapeutics Inc

Sosei Heptares

SteadyMed Therapeutics Inc

Stocosil Inc

Suda Pharmaceuticals Ltd

Sulfateq BV

Sun Pharma Advanced Research Company Ltd

Synokem Pharmaceuticals Ltd

Takeda Pharmaceutical Co Ltd

Target Medicals LLC

Theracos Inc

Theragene Pharmaceuticals Inc

Theravance Biopharma Inc

Topadur Pharma AG

Translate Bio Inc

Tritech Biopharmaceuticals Co Ltd

United Therapeutics Corp

Vascular BioSciences

VasThera Research Institute

Vectus Biosystems Ltd

Velocity Pharmaceutical Development LLC

VG Life Sciences Inc

Vivus Inc

Windtree Therapeutics Inc

XuanZhu Pharma Co Ltd

Yuhan Corp

Zhejiang Conba Pharmaceutical Co Ltd”

Tables and Figures

Table of Contents

Table of Contents

Table of Contents 2

Introduction 7

Hypertension Overview 8

Hypertension Therapeutics Development 9

Hypertension Therapeutics Assessment 34

Hypertension Companies Involved in Therapeutics Development 52

Hypertension Drug Profiles 103

Hypertension Dormant Projects 539

Hypertension Discontinued Products 556

Hypertension Product Development Milestones 558

Appendix 567

Reason to Buy

  • Current and future of Pharma & Healthcare Market outlook in the developed and emerging markets
  • Highlights key business priorities in order to assist companies to realign their business strategies
  • The segment that is expected to dominate the Pharma & Healthcare Market
  • Regions that are expected to witness the fastest growth during the forecast period
  • Identify the latest developments, Pharma & Healthcare Market shares, and strategies employed by the major market players
  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the global Pharma & Healthcare Market
  • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets